Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Cunningham

Showing results (371-380 of 393) with videos related to

Pageof 40
Sort By:
The Journal of Infectious Diseases|November 24, 2019
Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in ChildrenElizabeth J McFarland, Ruth A Karron, Petronella Muresan, et al.
The Journal of Infectious Diseases|February 2, 2020
Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in ChildrenElizabeth J McFarland, Ruth A Karron, Petronella Muresan, et al.
The Lancet. HIV|April 15, 2024
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm studyCarina A Rodriguez, Eva Natukunda, Renate Strehlau, et al.
The Journal of Infectious Diseases|March 7, 2018
Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in ChildrenElizabeth J McFarland, Ruth A Karron, Petronella Muresan, et al.
The Pediatric Infectious Disease Journal|April 12, 2017
The Nasopharyngeal Microbiota of Children With Respiratory Infections in BotswanaMatthew S Kelly, Michael G Surette, Marek Smieja, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 28, 2004
The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogsSu-Er W Huskey, Brian J Dean, George A Doss, et al.
Journal of Clinical Immunology|May 19, 2016
Hyper IgM Syndrome: a Report from the USIDNET RegistryEmily A Leven, Patrick Maffucci, Hans D Ochs, et al.
Journal of Virology|March 5, 2010
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccinationStephanie A Freel, Laurie Lamoreaux, Pratip K Chattopadhyay, et al.
The Journal of Infectious Diseases|May 19, 2021
Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn InfantsElizabeth J McFarland, Coleen K Cunningham, Petronella Muresan, et al.
Journal of Medicinal Chemistry|May 30, 1998
A potent, orally bioavailable benzazepinone growth hormone secretagogueR J DeVita, R Bochis, A J Frontier, et al.
Pageof 40

Showing results (371-380 of 393) with videos related to

Sort By:
Pageof 40
The Journal of Infectious Diseases|November 24, 2019
Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in ChildrenElizabeth J McFarland, Ruth A Karron, Petronella Muresan, et al.
The Journal of Infectious Diseases|February 2, 2020
Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in ChildrenElizabeth J McFarland, Ruth A Karron, Petronella Muresan, et al.
The Lancet. HIV|April 15, 2024
Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm studyCarina A Rodriguez, Eva Natukunda, Renate Strehlau, et al.
The Journal of Infectious Diseases|March 7, 2018
Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in ChildrenElizabeth J McFarland, Ruth A Karron, Petronella Muresan, et al.
The Pediatric Infectious Disease Journal|April 12, 2017
The Nasopharyngeal Microbiota of Children With Respiratory Infections in BotswanaMatthew S Kelly, Michael G Surette, Marek Smieja, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 28, 2004
The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogsSu-Er W Huskey, Brian J Dean, George A Doss, et al.
Journal of Clinical Immunology|May 19, 2016
Hyper IgM Syndrome: a Report from the USIDNET RegistryEmily A Leven, Patrick Maffucci, Hans D Ochs, et al.
Journal of Virology|March 5, 2010
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccinationStephanie A Freel, Laurie Lamoreaux, Pratip K Chattopadhyay, et al.
The Journal of Infectious Diseases|May 19, 2021
Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn InfantsElizabeth J McFarland, Coleen K Cunningham, Petronella Muresan, et al.
Journal of Medicinal Chemistry|May 30, 1998
A potent, orally bioavailable benzazepinone growth hormone secretagogueR J DeVita, R Bochis, A J Frontier, et al.
Pageof 40